For millions of women experiencing low libido, the treatment landscape has historically been limited. For years, the options were hormonal therapies with limited evidence for desire specifically, or simply being told that low sexual desire was a normal part of aging or stress — nothing to be done about it. That began to change with the FDA's approval of bremelanotide, marketed under the brand name Vyleesi, in June 2019.
Bremelanotide — originally studied as the peptide PT-141 — represents a genuinely different approach to female sexual dysfunction. Unlike hormonal treatments that work peripherally, PT-141 works centrally, in the brain, activating melanocortin receptors to restore the neurological signals that underlie sexual desire. It is not a hormone. It does not increase blood flow to the genitals. It targets the desire pathway itself.
This article covers everything you need to understand about PT-141 for women: what the science actually says, what the clinical trials found, the real side effect profile, who is and isn't a candidate, and how it compares to other options including the only other FDA-approved treatment in this space.
What Is PT-141 (Bremelanotide)?
PT-141 is the research name for bremelanotide, a synthetic peptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It was originally developed as a sunless tanning agent — researchers studying melanocortin peptides noticed, unexpectedly, that test participants reported increased sexual arousal as a side effect. This observation redirected the compound toward sexual medicine research.
Bremelanotide is classified as a melanocortin receptor agonist, specifically activating MC3R and MC4R receptor subtypes in the central nervous system. These receptors are distributed throughout brain regions involved in sexual motivation, reward, and behavioral response — a fundamentally different mechanism than anything previously approved for female sexual dysfunction.
The compound is administered as a subcutaneous injection (under the skin of the abdomen or thigh), typically 45 minutes to one hour before anticipated sexual activity. It is not taken daily — it's an on-demand medication.
FDA Approval: Vyleesi for HSDD
In June 2019, the FDA approved bremelanotide (brand name Vyleesi) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The full approval record, prescribing label, and regulatory correspondence are publicly available in the FDA's Drugs@FDA entry for Vyleesi (NDA 210557). This makes Vyleesi one of only two FDA-approved treatments for female sexual dysfunction — the other being flibanserin (Addyi), a daily oral pill approved in 2015.
What Is HSDD?
Hypoactive sexual desire disorder is defined as persistently or recurrently deficient or absent sexual desire — not explained by another medical or psychological condition, not caused by a relationship problem, not a result of normal life stress, and causing significant personal distress. The "distress" criterion is critical: HSDD is not simply having less interest in sex than a partner. It's low desire that the woman herself finds distressing.
HSDD affects an estimated 8–10% of premenopausal women in the United States. For many, it profoundly impacts quality of life, self-perception, and intimate relationships. Until Addyi's approval in 2015, there were no FDA-approved treatments specifically for this condition.
What the Approval Covers — and What It Doesn't
The FDA approval specifically covers premenopausal women with HSDD. This is important for several reasons:
- Postmenopausal women with low libido may have different contributing factors (primarily hormonal) and may be better served by other approaches
- HSDD associated with another medical condition (e.g., thyroid disorder, depression, medication side effects) requires that the underlying condition be addressed first
- Low desire caused by relationship distress or contextual factors does not meet the HSDD criteria and is not an approved indication
How Bremelanotide Works in the Brain
The mechanism of PT-141 is what makes it genuinely different from everything that came before it in sexual medicine.
The Melanocortin System
Melanocortin receptors (MC1R through MC5R) are found throughout the body and brain, serving diverse functions from pigmentation to energy balance to sexual function. The MC3R and MC4R subtypes, which PT-141 primarily targets, are found in abundance in the hypothalamus and limbic system — brain regions central to desire, motivation, and reward processing.
Sexual desire is not simply a physical reflex — it begins in the brain. The brain must interpret internal signals and environmental context and generate the motivational state we recognize as desire. The melanocortin system appears to play a regulatory role in this initiation process.
How PT-141 Activates This Pathway
When bremelanotide binds to MC3R and MC4R receptors, it activates a cascade of neurological signaling in areas including the hypothalamus, medial preoptic area, and ventral tegmental area. Studies suggest this activation may increase dopaminergic signaling — essentially amplifying the brain's natural desire-generating pathway.
Crucially, this mechanism does not depend on hormonal status. PT-141 does not change estrogen, progesterone, or testosterone levels. This is why it may be effective for women whose low libido is not primarily hormonal in origin — which represents a significant portion of women with HSDD.
Central vs. Peripheral Action
Previous attempts at female sexual dysfunction treatments focused on the periphery — increasing blood flow to the genitals, improving genital sensation, or addressing vaginal symptoms. PT-141's central action is a meaningful departure. It targets the desire pathway itself — the motivation to engage in sexual activity — rather than downstream physical responses.
What Clinical Trials Show
The FDA approval of Vyleesi was based on two Phase 3 randomized, double-blind, placebo-controlled trials — known as the RECONNECT studies — involving premenopausal women diagnosed with HSDD. Both trials ran for 24 weeks and used validated patient-reported outcome measures to assess sexual desire and distress; the full peer-reviewed results are indexed in the NIH/PubMed record of the RECONNECT trial publication in Obstetrics & Gynecology.
Primary Outcomes
In the pivotal trials, bremelanotide demonstrated statistically significant improvements in both co-primary endpoints compared to placebo:
- Sexual desire: Women receiving bremelanotide showed significantly greater improvements in their desire scores on the Female Sexual Function Index (FSFI) compared to placebo
- Sexual distress: Participants reported significantly greater reductions in distress related to low sexual desire on the Female Sexual Distress Scale - Desire/Arousal/Orgasm (FSDS-DAO) compared to placebo
It's worth noting how clinical trial results in sexual medicine should be interpreted. "Statistically significant" means the improvement was real and not due to chance. The magnitude of improvement varied among participants — as with any CNS-active compound, individual response differs based on neurobiology, baseline status, and contributing factors to low desire.
What Responders Reported
Participants who responded to bremelanotide described it as a restoration of desire rather than a manufactured or artificial response. They reported increased interest in sexual activity, reduced distress about their low libido, and in many cases, improved relationship satisfaction. A subset of women experienced little to no effect — consistent with the expected variability in any centrally-acting compound.
What the Trials Did Not Show
Bremelanotide did not significantly improve orgasm, arousal, or lubrication as primary outcomes in these trials. Its approved indication is specifically desire and the distress associated with low desire — not the full spectrum of female sexual dysfunction. Women whose primary concern is arousal, sensation, or orgasmic difficulty may not be the best candidates.
Interested in women's wellness protocols?
Join the Nuvari waitlist to be notified when our physician-directed women's health protocols are available in your area.
Join the Waitlist →Side Effects and Safety Profile
Understanding the side effect profile of PT-141 is essential for making an informed decision. The most commonly reported side effects from the pivotal clinical trials were:
Nausea
Nausea was the most frequently reported side effect, occurring in approximately 40% of participants in the trials (versus about 1% in placebo groups). In most cases, nausea was mild to moderate and resolved within a few hours. For a meaningful subset of participants, it was significant enough to limit use. Pre-treating with an anti-nausea medication prior to injection may help — this is worth discussing with your provider.
Flushing
Facial flushing (redness, warmth) was reported by approximately 20% of participants. Like nausea, flushing is transient and typically resolves within hours. It's consistent with melanocortin receptor activation, which also plays a role in skin vasodilation.
Headache
Headache was reported by approximately 11% of participants, usually mild and resolving without intervention.
Injection Site Reactions
Localized reactions at the injection site — redness, bruising, mild discomfort — were reported and are typical of any subcutaneous injection. Rotating injection sites and proper technique minimize these effects.
Transient Blood Pressure Changes
Bremelanotide may transiently decrease blood pressure in some women and is not recommended for women with cardiovascular disease or uncontrolled hypertension. Providers will assess cardiovascular risk before prescribing, and it is typically recommended that women lie down for 30–60 minutes after injection if blood pressure effects are a concern.
Hyperpigmentation
A small percentage of women using bremelanotide (particularly those with darker skin tones) reported focal hyperpigmentation — darkening of the face, breasts, or gums — with repeated use. This is consistent with the compound's melanocortin activity on pigmentation. This side effect was generally reversible upon discontinuation.
Who Is a Candidate?
PT-141 is a good option to discuss with a provider if you are:
- A premenopausal woman experiencing low sexual desire
- Experiencing desire loss that you find personally distressing (not just different from your partner's level)
- Without a clear underlying cause that should be addressed first (untreated depression, thyroid dysfunction, medication side effects, relationship discord)
- Not pregnant or breastfeeding
- Without a history of significant cardiovascular disease or uncontrolled hypertension
- Willing to use an injectable medication on an as-needed basis
PT-141 may be a less appropriate option if your low libido is primarily driven by pain with intercourse, vaginal dryness, hormonal shifts from perimenopause or menopause, a relationship-based conflict, or a mental health condition that hasn't been addressed. In those cases, treating the root cause first — or alongside PT-141 — is likely to produce better outcomes.
PT-141 vs. Other Options for Female Sexual Dysfunction
Flibanserin (Addyi)
Both are FDA-approved for HSDD in premenopausal women, but they differ meaningfully. Flibanserin is a daily oral pill that modulates serotonin and dopamine receptor activity over time. It takes 4–8 weeks of consistent daily use to assess effect, requires abstaining from alcohol (due to hypotension risk), and cannot be stopped and started on a schedule. PT-141 is on-demand — taken when desired, on the days it's wanted. For women who prefer not to take a daily medication, PT-141's flexibility is a meaningful advantage.
Hormone Therapy
Estrogen, progesterone, and low-dose testosterone are used off-label in women for various sexual health concerns, including libido. These approaches are particularly relevant for postmenopausal women whose desire loss is hormonal in origin. For premenopausal women without clear hormonal deficiency, the evidence for hormone therapy improving desire specifically is less robust. PT-141 does not affect hormone levels and works through an entirely different mechanism.
Ospemifene and Vaginal Lubricants
These address vaginal dryness and pain with intercourse — different symptoms from low desire. They may be complementary to PT-141 in women who have both desire and physical concerns, but they are not alternatives to bremelanotide for desire specifically.
Compounded vs. Brand-Name Bremelanotide
Vyleesi (the brand-name version) is FDA-approved and available through traditional pharmacies with a prescription. It is typically packaged as a single-use autoinjector at 1.75 mg per dose.
Compounded bremelanotide is prepared by licensed compounding pharmacies and typically costs significantly less than the brand-name version. Compounded versions are available in various concentrations and may offer dosing flexibility — some providers prescribe lower starting doses to minimize nausea while gauging response.
The FDA has raised concerns about compounded versions of FDA-approved drugs in general, but compounding from a PCAB-accredited or licensed 503A pharmacy using pharmaceutical-grade ingredients is legal and widely used for many compounds. Discuss the options with your provider — what matters most is that you're getting medication from a licensed, reputable pharmacy with transparent sourcing.
Frequently Asked Questions
Is PT-141 FDA-approved for women?
Yes. Bremelanotide (brand name Vyleesi) received FDA approval in June 2019 specifically for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. This makes it one of only two FDA-approved treatments for female sexual dysfunction.
How long does PT-141 take to work?
PT-141 is designed to be administered 45 minutes to 1 hour before anticipated sexual activity. Effects in clinical trials were observed within this window. The medication is not a hormone and does not build up in the system — each dose works acutely rather than cumulatively.
What are the most common side effects of PT-141 in women?
The most common side effects reported in clinical trials include nausea (the most frequent), flushing, headache, and injection site reactions (redness, discomfort). Transient blood pressure changes were also observed. Most side effects are mild to moderate and resolve within a few hours.
What is the difference between PT-141 and flibanserin (Addyi)?
Both are FDA-approved for HSDD in premenopausal women, but they work differently. Flibanserin (Addyi) is a daily oral pill that modulates serotonin and dopamine over time. PT-141 (bremelanotide/Vyleesi) is an injectable taken acutely before sexual activity, working via melanocortin receptors in the brain. PT-141 is considered more flexible since it's used on-demand rather than daily.
Can I get PT-141 through a telehealth provider?
Yes. PT-141 can be prescribed by telehealth providers in most US states. Both the brand-name Vyleesi and compounded bremelanotide are available through licensed platforms with a physician evaluation and prescription.